Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd surged to its upper circuit limit on 3 February 2026, propelled by robust buying interest and significant investor participation. The stock closed at ₹37.90, marking a 4.99% gain on the day, outperforming its sector and the broader market indices.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 2 Feb 2026, hitting its lower circuit price limit of ₹32.68. The stock endured intense selling pressure, culminating in a maximum daily loss of 4.97%, marking its ninth consecutive day of decline and signalling mounting investor panic amid deteriorating fundamentals.

Mangalam Drugs and Organics Ltd witnessed a sharp decline on 1 Feb 2026, hitting its lower circuit limit of 5%, closing at ₹34.39. The stock faced intense selling pressure, marking its eighth consecutive day of losses and underperforming the Pharmaceuticals & Biotechnology sector by over 5% today.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 30 Jan 2026, hitting its lower circuit price limit of ₹36.20. The stock endured intense selling pressure, closing with a maximum daily loss of 4.99%, marking its seventh consecutive day of decline and signalling heightened investor anxiety.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 29 Jan 2026, hitting its lower circuit price limit of ₹38.10. The stock suffered a maximum daily loss of 4.99%, reflecting intense selling pressure and panic among investors amid deteriorating market sentiment and weak trading volumes.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 28 Jan 2026, hitting its lower circuit price limit of ₹40.1. The stock endured intense selling pressure, closing with a maximum daily loss of 5.0%, reflecting mounting investor concerns and a continuation of a bearish trend that has seen the share price fall by over 22% in the past five trading sessions.

Mangalam Drugs and Organics Ltd witnessed intense selling pressure on 27 Jan 2026, triggering the stock to hit its lower circuit limit of 5%, closing at ₹42.21. This marks the fourth consecutive day of decline, with the stock shedding 18.53% over this period, signalling heightened investor anxiety and a sharp loss of confidence in the micro-cap pharmaceutical player.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Mangalam Drugs and Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 23 Jan 2026 as it hit its lower circuit price limit of ₹44.43, marking a maximum daily loss of 4.98%. The stock’s performance reflects intense selling pressure and a significant drop in investor participation, signalling growing concerns among market participants.

Shares of Mangalam Drugs and Organics Ltd plunged to their lower circuit limit on 22 Jan 2026, tumbling 5.0% to close at ₹46.76. The stock faced intense selling pressure, with volumes rising despite the sharp fall, signalling panic selling and unfilled supply overwhelming demand in the Pharmaceuticals & Biotechnology sector.

Mangalam Drugs and Organics Ltd witnessed a significant surge on 21 Jan 2026, hitting its upper circuit limit of 5% to close at ₹54.40. This sharp move was driven by robust buying interest, resulting in the stock outperforming its sector and broader market indices despite a recent trend reversal. However, regulatory restrictions have frozen further trading, leaving a substantial unfilled demand in the market.

Mangalam Drugs and Organics Ltd surged to its upper circuit limit on 20 Jan 2026, closing at ₹51.81 with a maximum daily gain of 4.98%. This marks the 16th consecutive day of gains, reflecting robust investor interest despite a micro-cap market capitalisation of ₹78 crore. The stock outperformed its Pharmaceuticals & Biotechnology sector by 5.59% and the broader Sensex by nearly 5.5%, underscoring strong buying momentum and persistent demand.

Mangalam Drugs and Organics Ltd surged to its upper circuit price limit on 19 Jan 2026, reflecting intense buying interest and a remarkable 5.0% gain in a single trading session. The stock’s performance outpaced its sector and benchmark indices, signalling renewed investor confidence despite a cautious backdrop.

Mangalam Drugs and Organics Ltd surged to its upper circuit limit on 14 Jan 2026, closing at ₹44.77, marking a 5.0% gain on the day. This marks the 13th consecutive day of gains for the pharmaceutical micro-cap, reflecting robust investor interest despite a backdrop of subdued sector performance and falling delivery volumes.

Mangalam Drugs and Organics Ltd surged to its upper circuit price limit on 12 Jan 2026, reflecting robust buying interest and a remarkable 4.99% gain in a single trading session. The stock’s performance outpaced its sector and benchmark indices, signalling heightened investor enthusiasm despite a prevailing strong sell rating from MarketsMOJO.

Mangalam Drugs and Organics Ltd surged to hit its upper circuit limit on 9 Jan 2026, propelled by robust buying interest and a significant price gain of 4.99% in a single trading session. The pharmaceutical micro-cap stock demonstrated exceptional momentum, outperforming its sector and broader market indices despite subdued investor participation.